Stock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar Health

NEW YORK, September 18, 2017 /PRNewswire/ --

If you want a Stock Review on GALE, IDRA, RXDX, or JAGX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, the NASDAQ Composite ended the day at 6,448.47, up 0.30%; the Dow Jones Industrial Average edged 0.29% higher, to finish at 22,268.34; and the S&P 500 closed at 2,500.23, marginally gaining 0.18%. Gains were broad based as six out of nine sectors finished the trading session in green. DailyStockTracker.com has initiated research reports on the following Biotechnology stocks: Galena Biopharma Inc. (NASDAQ: GALE), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Ignyta Inc. (NASDAQ: RXDX), and Jaguar Health Inc. (NASDAQ: JAGX). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:

http://dailystocktracker.com/register/

Galena Biopharma 

San Ramon, California-based Galena Biopharma Inc.'s stock finished Friday's session 4.14% higher at $0.36. A total volume of 656,938 shares was traded, which was above its three months average of 622.58 thousand shares. Shares of the Company are trading below their 50-day moving average by 21.07%. Moreover, shares of Galena Biopharma, which develops hematology and oncology therapeutics that address unmet medical needs, have a Relative Strength Index (RSI) of 42.61. GALE complete research report is just a click away and free at:

http://dailystocktracker.com/registration/?symbol=GALE

Idera Pharmaceuticals 

Shares in Cambridge, Massachusetts-based Idera Pharmaceuticals Inc. rose 5.50%, ending last Friday's session at $2.11. A total volume of 1.77 million shares was traded, which was above its three months average of 904.62 thousand shares. The stock has gained 19.89% in the past month, 32.70% in the previous three months, and 40.67% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 13.27% and 15.56%, respectively. Moreover, shares of Idera Pharma, which focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the US, have an RSI of 60.51. The complimentary report on IDRA can be downloaded at:

http://dailystocktracker.com/registration/?symbol=IDRA

Ignyta 

On Friday, San Diego, California headquartered Ignyta Inc.'s stock saw a rise of 2.64%, to close the day at $11.65. A total volume of 3.78 million shares was traded, which was higher than their three months average volume of 923.88 thousand shares. The Company's shares have advanced 18.88% in the last one month, 18.27% in the previous three months, 99.15% over the last twelve months, and 119.81% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 17.71% and 44.17%, respectively. Additionally, shares of Ignyta, which engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases, have an RSI of 63.57. Sign up for your complimentary research report on RXDX at:

http://dailystocktracker.com/registration/?symbol=RXDX

Jaguar Health 

Shares in San Francisco, California-based Jaguar Health Inc. ended the day 16.60% lower at $0.42. A total volume of 752,772 shares was traded, which was above their three months average volume of 620.46 thousand shares. The stock has gained 10.32% in the last one month. The Company's shares are trading below their 50-day moving average by 19.49%. Furthermore, shares of Jaguar Health, which focuses on developing and commercializing novel gastrointestinal prescription products from plants, have an RSI of 42.61. Get free access to your research report on JAGX at:

http://dailystocktracker.com/registration/?symbol=JAGX

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com